Pharma Report on Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2020


Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2020


Graft Versus Host Disease – Pipeline Review, H2 2020, provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient’s body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

Report Highlights

Graft Versus Host Disease – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 12, 38, 15, 3, 39, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 1 molecules, respectively.

Graft Versus Host Disease (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (Immunology).
– The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Graft Versus Host Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (Immunology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
AbbVie Inc
Adienne Pharma & Biotech
AltruBio Inc
Amgen Inc
AnaptysBio Inc
apceth Biopharma GmbH
ASC Therapeutics Inc
AstraZeneca Plc
Athersys Inc
Autolus Therapeutics Plc
Bellicum Pharmaceuticals Inc
Biocon Ltd
Biogen Inc
BioIncept LLC
BioTheryX Inc
BlueRock Therapeutics
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cellect Biotechnology Ltd
Cellective BioTherapy Inc
Cellix Bio Pvt Ltd
CheckPoint Immunology Inc
Clinigen Group Plc
CTI BioPharma Corp
Cytodyn Inc
Cytopeutics Pte Ltd
Daewoong Pharmaceutical Co Ltd
Dualogics Corp
Educell doo
Eli Lilly and Co
enGene Inc
Enlivex Therapeutics Ltd
Evive Biotech
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fujifilm Holdings Corp
Genentech USA Inc
GigaGen Inc
GlaxoSmithKline Plc
Glia LLC
Humanigen Inc
iCELL Biotechnology Co Ltd
Immune Modulation Inc
ImmuneTarget Inc
Imstem Biotechnology Inc
Incyte Corp
Inspyr Therapeutics Inc
Jazz Pharmaceuticals Plc
JN Biosciences LLC
Kadmon Corp LLC
Kalytera Therapeutics Inc
Kamada Ltd
Kiniksa Pharmaceuticals Ltd
Kymab Ltd
LG Chem Ltd
MaaT Pharma
Machavert Pharmaceuticals LLC
Magenta Therapeutics Inc
Mallinckrodt Plc
Medexus Pharmaceuticals Inc
Medicenna Therapeutics Corp
Mediolanum farmaceutici SpA
Medsenic SAS
Mereo Biopharma Group Plc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
MitoImmune Therapeutics Inc
NapaJen Pharma Inc
Neovii Pharmaceuticals AG
Nurix Therapeutics Inc
OncoImmune Inc
OSE Immunotherapeutics
Panorama Research Inc
Pfizer Inc
Platinum Biotech (Beijing) Co Ltd
Pluristem Therapeutics Inc
Precision Biosciences Inc
SCM lifescience Co Ltd
Seattle Genetics Inc
Secura Bio Inc
Seres Therapeutics Inc
Shenzhen Chipscreen Biosciences Co Ltd
STERO Biotechs Ltd
StingInn LLC
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Syndax Pharmaceuticals Inc
Synthetic Biologics Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TeraImmune Inc
TGV Laboratories Inc
United BioPharma Inc
Vault Pharma Inc
Visterra Inc
Xenikos BV
Xenothera SAS
XL-protein GmbH

For queries regarding this report:

Contact Us:
Ritesh Tiwari, Director
USA: +1-800-416-3124

Follow us on Social Media:

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: *Industry Press Release is a part of Research By Markets.